Which Columvi (glofitamab) patent are people talking about?
“Columvi patent” usually refers to the intellectual property covering glofitamab, the CD20xCD3 bispecific antibody marketed as Columvi for certain relapsed/refractory large B-cell lymphomas. The patent landscape can include different kinds of protection, such as (1) composition-of-matter patents for the molecule, (2) method-of-use patents for specific treatment regimens, and (3) additional patent families filed around clinical use, dosing, or related technical aspects.
When do Columvi patents expire (and when could generics or biosimilars arrive)?
Patent expiry dates depend on the specific patent family and jurisdiction (US vs. Europe vs. other countries). Even after primary patents expire, regulatory market-entry timing can still be delayed by secondary patents (e.g., method-of-use claims), patent-term adjustments, pediatric exclusivity, and litigation outcomes. Without the specific patent number or country, an exact “expiry date for Columvi” can’t be stated reliably.
Are there patents that block biosimilars or competitors for Columvi?
For biologics and antibody products, competitors typically look for ways around specific claims. That can mean:
- challenging the validity of claims in court,
- designing around the claimed molecule or claimed dosing/treatment method,
- or waiting until the relevant claims expire or are no longer enforceable in a given jurisdiction.
What do people search for when they say “Columvi patent” in 2026?
Search patterns typically include:
- “glofitamab patent expiration date”
- “Columvi Orange Book / patent list” (US)
- “EPO patent glofitamab”
- “Columvi biosimilar challenge” or “glofitamab litigation”
- “which patents cover Columvi in [country/state]”
These searches usually aim to identify which exact patents cover the product and whether any are listed for regulatory purposes.
Can you give me the exact Columvi patent details?
If you share one of the following, I can narrow it down precisely:
- the country/jurisdiction (US, EU/EP, UK, etc.),
- the patent number (or a link to the patent listing),
- or a screenshot/text of the patent entry you’re looking at.
Sources
No sources were provided with your message, and I don’t have access to a live patent database from here.